Bezbaruah Rajashri, Chavda Vivek P, Nongrang Lawandashisha, Alom Shahnaz, Deka Kangkan, Kalita Tutumoni, Ali Farak, Bhattacharjee Bedanta, Vora Lalitkumar
Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India.
Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380008, Gujarat, India.
Vaccines (Basel). 2022 Nov 17;10(11):1946. doi: 10.3390/vaccines10111946.
Vaccination is still the most cost-effective way to combat infectious illnesses. Conventional vaccinations may have low immunogenicity and, in most situations, only provide partial protection. A new class of nanoparticle-based vaccinations has shown considerable promise in addressing the majority of the shortcomings of traditional and subunit vaccines. This is due to recent breakthroughs in chemical and biological engineering, which allow for the exact regulation of nanoparticle size, shape, functionality, and surface characteristics, resulting in improved antigen presentation and robust immunogenicity. A blend of physicochemical, immunological, and toxicological experiments can be used to accurately characterize nanovaccines. This narrative review will provide an overview of the current scenario of the nanovaccine.
接种疫苗仍然是对抗传染病最具成本效益的方法。传统疫苗可能免疫原性较低,并且在大多数情况下只能提供部分保护。一类新型的基于纳米颗粒的疫苗在解决传统疫苗和亚单位疫苗的大多数缺点方面显示出了巨大的前景。这得益于化学和生物工程领域的最新突破,这些突破使得能够精确调控纳米颗粒的大小、形状、功能和表面特性,从而改善抗原呈递并增强免疫原性。可以通过物理化学、免疫学和毒理学实验的综合运用来准确表征纳米疫苗。本叙述性综述将概述纳米疫苗的当前情况。